Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma: a Multicenter, Single Arm, Phase II Study
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Sintilimab (Primary)
- Indications Hodgkin's disease
- Focus Registrational; Therapeutic Use
- Acronyms ORIENT-1
- Sponsors Innovent Biologics
- 05 Jun 2018 Results (data cut off: 8 feb, 2018; n=96) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 16 May 2018 Results from this trial (n=96) will be presented at the American Society Of Clinical Oncology Annual Meeitng (June 2018).
- 16 May 2018 Status changed from not yet recruiting to recruiting, according to an Innovent Biologics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History